Ibrutinib-Based Therapy Reinvigorates CD8 T Cells Compared to Chemoimmunotherapy: Immune-Monitoring From the E1912 Trial

Scientists performed longitudinal immunophenotypic and functional analysis of pre- and on-treatment peripheral blood samples from patients in the Phase III E1912 trial comparing ibrutinib-rituximab to fludarabine, cyclophosphamide and rituximab.